Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$9.16 USD
-0.08 (-0.87%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $9.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Maravai LifeSciences Holdings, Inc. [MRVI]
Reports for Purchase
Showing records 1 - 20 ( 72 total )
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for MRVI 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
3Q Light, Positive EBITDA, LT Goal Reiterated
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Investor Day - Post-Pandemic Portfolio Provides More Ways to Win
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
2Q23 - FY23 Finally De-Risked? Downgrade to Sector Weight
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Chatter of Buyer (Again) and Comparables
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Risk Factors for Life Science May Be de Minimis
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
4Q22 in Line and FY23 Guidance Sets the Stage for LT Potential
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
ChatGPT / Generative AI Creating a Significant Opportunity for NVDA, but Challenges Exist
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Triangulating mRNA Potential, Revised Model, More Clarity
Provider: KeyBanc Capital Markets
Analyst: Research Department